JP2021519785A5 - - Google Patents

Info

Publication number
JP2021519785A5
JP2021519785A5 JP2020552868A JP2020552868A JP2021519785A5 JP 2021519785 A5 JP2021519785 A5 JP 2021519785A5 JP 2020552868 A JP2020552868 A JP 2020552868A JP 2020552868 A JP2020552868 A JP 2020552868A JP 2021519785 A5 JP2021519785 A5 JP 2021519785A5
Authority
JP
Japan
Prior art keywords
item
compound
pharmaceutically acceptable
acceptable salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519785A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024729 external-priority patent/WO2019191526A1/en
Publication of JP2021519785A publication Critical patent/JP2021519785A/ja
Publication of JP2021519785A5 publication Critical patent/JP2021519785A5/ja
Pending legal-status Critical Current

Links

JP2020552868A 2018-03-30 2019-03-29 共有結合性メニン阻害剤としてのピペリジン化合物 Pending JP2021519785A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862650777P 2018-03-30 2018-03-30
US62/650,777 2018-03-30
US201862740549P 2018-10-03 2018-10-03
US62/740,549 2018-10-03
PCT/US2019/024729 WO2019191526A1 (en) 2018-03-30 2019-03-29 Piperidine compounds as covalent menin inhibitors

Publications (2)

Publication Number Publication Date
JP2021519785A JP2021519785A (ja) 2021-08-12
JP2021519785A5 true JP2021519785A5 (cg-RX-API-DMAC10.html) 2022-04-06

Family

ID=68060814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552868A Pending JP2021519785A (ja) 2018-03-30 2019-03-29 共有結合性メニン阻害剤としてのピペリジン化合物

Country Status (14)

Country Link
US (1) US20210115018A1 (cg-RX-API-DMAC10.html)
EP (1) EP3774731A4 (cg-RX-API-DMAC10.html)
JP (1) JP2021519785A (cg-RX-API-DMAC10.html)
KR (1) KR20200136958A (cg-RX-API-DMAC10.html)
CN (1) CN111936465A (cg-RX-API-DMAC10.html)
AU (1) AU2019243587A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020020059A2 (cg-RX-API-DMAC10.html)
CA (1) CA3093454A1 (cg-RX-API-DMAC10.html)
IL (1) IL277659A (cg-RX-API-DMAC10.html)
MX (1) MX2020010181A (cg-RX-API-DMAC10.html)
PH (1) PH12020551580A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202009543VA (cg-RX-API-DMAC10.html)
TW (1) TW202003465A (cg-RX-API-DMAC10.html)
WO (1) WO2019191526A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
US10807951B2 (en) 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
EP3860978A1 (en) * 2018-10-03 2021-08-11 The Regents Of The University Of Michigan Small molecule menin inhibitors
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為menin抑制劑之六氫吡啶化合物
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
IL328224A (en) * 2023-11-17 2026-07-01 Kura Oncology Inc Methods for treating KIT-positive cancer with a menin inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
CN109415337B (zh) * 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
EP3600313A4 (en) * 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS

Similar Documents

Publication Publication Date Title
JP2024543982A5 (cg-RX-API-DMAC10.html)
JP2020007311A5 (cg-RX-API-DMAC10.html)
JP2022515197A5 (cg-RX-API-DMAC10.html)
JP2024543976A5 (cg-RX-API-DMAC10.html)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2017526675A5 (cg-RX-API-DMAC10.html)
CN114174303B (zh) 作为sting激动剂的大环化合物及其方法和用途
JP2014511840A5 (cg-RX-API-DMAC10.html)
JP2017509586A5 (cg-RX-API-DMAC10.html)
JP2016509047A5 (cg-RX-API-DMAC10.html)
JP2020511467A5 (cg-RX-API-DMAC10.html)
JP2018530549A5 (cg-RX-API-DMAC10.html)
JP2018516917A5 (cg-RX-API-DMAC10.html)
JP2016506916A5 (cg-RX-API-DMAC10.html)
JP2017525730A5 (cg-RX-API-DMAC10.html)
JP2008510770A5 (cg-RX-API-DMAC10.html)
JP2021534106A5 (cg-RX-API-DMAC10.html)
JP2014511891A5 (cg-RX-API-DMAC10.html)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP2015522650A5 (cg-RX-API-DMAC10.html)
JP2019501130A5 (cg-RX-API-DMAC10.html)
JP2017519754A5 (cg-RX-API-DMAC10.html)
JP2014508804A5 (cg-RX-API-DMAC10.html)
JP2023512557A5 (cg-RX-API-DMAC10.html)
JP2019529419A5 (cg-RX-API-DMAC10.html)